{"version":"1.0","provider_name":"Pharma Trend","provider_url":"https:\/\/pharma-trend.com\/en","author_name":"Business Wire","author_url":"https:\/\/pharma-trend.com\/en\/author\/business\/","title":"BioAesthetics Announces Additional Clinical Study for NACgraft - Pharma Trend","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"HqVQGvjRY4\"><a href=\"https:\/\/pharma-trend.com\/en\/bioaesthetics-announces-additional-clinical-study-for-nacgraft\/\">BioAesthetics Announces Additional Clinical Study for NACgraft<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/pharma-trend.com\/en\/bioaesthetics-announces-additional-clinical-study-for-nacgraft\/embed\/#?secret=HqVQGvjRY4\" width=\"600\" height=\"338\" title=\"&#8220;BioAesthetics Announces Additional Clinical Study for NACgraft&#8221; &#8212; Pharma Trend\" data-secret=\"HqVQGvjRY4\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/pharma-trend.com\/en\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"NACgraft Aims to Improve Quality-of-Life for Breast Cancer Patients RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211;BioAesthetics Corporation today announced an additional clinical study for the BioAesthetics\u00ae NACgraft\u2122 Acellular Allograft that will investigate its performance in subpopulations of breast cancer survivors and other individuals needing nipple reconstruction. The previously announced study at Stanford Medicine focuses on female breast ... [Read more...]","thumbnail_url":"https:\/\/mms.businesswire.com\/media\/20220804005199\/en\/826995\/21\/2017-9-5_BioAesthetics_logo_high_res_xparent_bkgd.jpg"}